Skip to main content
Ajanta Pharma Ltd. logo

Ajanta Pharma Ltd. — Investor Relations & Filings

Ticker · AJANTPHARM ISIN · INE031B01049 LEI · 3358008XLYJJZBFBCK12 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2022-10-31 Regulatory Filings
Country IN India
Listing BSE.NS AJANTPHARM

About Ajanta Pharma Ltd.

https://www.ajantapharma.com

Ajanta Pharma Ltd. is a specialty pharmaceutical organization engaged in the development, manufacturing, and marketing of high-quality finished dosage formulations. The company maintains a significant presence in specialized therapeutic segments, including ophthalmology, dermatology, cardiology, and pain management. It operates advanced research and development centers dedicated to creating complex generics and first-to-market products. With a global footprint, the firm serves diverse healthcare needs across the United States and various emerging markets in Asia and Africa. Its manufacturing infrastructure comprises multiple state-of-the-art facilities designed to meet international regulatory standards, ensuring the delivery of effective and affordable healthcare solutions. The company's strategic focus remains on niche product categories and branded generics, supported by a robust supply chain and a commitment to innovation in drug delivery systems.

Recent filings

Filing Released Lang Actions
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding a significant increase in the trading volume of the company's shares. It clarifies that the increase is due to market dynamics and not due to any undisclosed material information. The letter references compliance with SEBI Listing Regulations and mentions a block deal on a specific date. The content is a regulatory clarification or explanation rather than a financial report, earnings release, or management discussion. The document length is short (2264 characters) and it does not contain financial statements or detailed financial data. It is not an announcement of a report publication but a regulatory communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2022-10-31 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is an announcement about an upcoming earnings conference call scheduled for November 3, 2022, including dial-in details and correction of a previous communication. It does not contain any actual financial results or substantive financial data but rather informs about the event where such results will be discussed. The document length is short (2892 characters) and serves as a notification rather than a report or transcript. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about the earnings call, not the earnings release itself or the call transcript.
2022-10-28 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 70% confidence The document is a notification about an upcoming earnings conference call scheduled for November 3, 2022, following the release of Q2 FY 2023 unaudited financial results. It includes details about the call timing, dial-in numbers, and playback information. The document does not contain actual financial results or substantive financial data but rather announces the event where such results will be discussed. According to the classification rules, announcements of earnings calls or schedules without the actual financial results or transcripts are classified as Call Transcript (CT) only if they contain the full transcript, which this document does not. It is an announcement of the earnings call event itself. Therefore, the best fitting category is Call Transcript (CT) as it relates to the earnings conference call, but since it is only an announcement and not a transcript, the closest category is Call Transcript (CT) with moderate confidence. However, given the document is purely an announcement of the earnings call schedule and not the transcript, the classification should be Call Transcript (CT) with a confidence reflecting it is an announcement of the call, not the transcript itself.
2022-10-27 English
Board Meeting — Financial results
Regulatory Filings Classification · 95% confidence The document is a notice informing about an upcoming Board meeting scheduled to consider and take on record the unaudited consolidated and standalone financial results for the quarter and half year ended 30th September 2022. It is a short announcement notifying the market and stakeholders about the meeting date and agenda, specifically the financial results review. It does not contain the financial results themselves or detailed financial data. The document is under 5,000 characters and serves as a notification rather than a report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about a board meeting and upcoming financial results, not the financial report itself or a detailed management discussion.
2022-10-21 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Ajanta Pharma Ltd. has been awarded as one of India’s Best Managed Companies by Deloitte for 2022. It contains no financial statements, no detailed financial performance data, no regulatory filings, no voting results, no management changes, no earnings data, and no other formal report content. It is a corporate announcement about an award received, not a financial or regulatory report. The document length is 4803 characters, which is relatively short and consistent with a press release. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-10-17 English
General updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges, referencing a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2022. It mentions the certificate is enclosed and requests the exchanges to take it on record. The document length is only 1285 characters, indicating it is a brief regulatory communication rather than a full report. There is no financial data or detailed report content present. This fits the pattern of a Regulatory Filing (RNS), which covers compliance documents and official regulatory communications that do not constitute full reports.
2022-10-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.